Q2 2025 Earnings Estimate for Pacira BioSciences, Inc. Issued By Zacks Research (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for Pacira BioSciences in a report released on Friday, April 26th. Zacks Research analyst R. Department now anticipates that the company will earn $0.66 per share for the quarter, down from their previous forecast of $0.67. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.18 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.80 EPS and Q1 2026 earnings at $0.72 EPS.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, meeting the consensus estimate of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The firm had revenue of $181.24 million during the quarter, compared to analysts’ expectations of $180.60 million.

PCRX has been the subject of several other reports. TheStreet raised Pacira BioSciences from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Wedbush reissued an “outperform” rating and set a $57.00 price target on shares of Pacira BioSciences in a research report on Thursday, February 8th. Royal Bank of Canada reduced their price target on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Needham & Company LLC reissued a “buy” rating and set a $45.00 price target on shares of Pacira BioSciences in a research report on Tuesday, April 9th. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research note on Monday, March 4th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Pacira BioSciences presently has a consensus rating of “Buy” and a consensus price target of $49.50.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX opened at $26.33 on Monday. The stock has a 50 day moving average price of $28.71 and a 200 day moving average price of $29.63. Pacira BioSciences has a 52 week low of $25.33 and a 52 week high of $48.60. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. The stock has a market capitalization of $1.22 billion, a PE ratio of 32.51 and a beta of 0.76.

Hedge Funds Weigh In On Pacira BioSciences

Large investors have recently made changes to their positions in the company. abrdn plc increased its stake in Pacira BioSciences by 14.3% during the 4th quarter. abrdn plc now owns 448,691 shares of the company’s stock worth $15,139,000 after acquiring an additional 56,081 shares during the period. Gradient Investments LLC increased its stake in Pacira BioSciences by 33.0% during the 4th quarter. Gradient Investments LLC now owns 139,949 shares of the company’s stock worth $4,722,000 after acquiring an additional 34,723 shares during the period. Gotham Asset Management LLC increased its stake in Pacira BioSciences by 16.8% during the 3rd quarter. Gotham Asset Management LLC now owns 22,317 shares of the company’s stock worth $685,000 after acquiring an additional 3,203 shares during the period. Assenagon Asset Management S.A. increased its stake in Pacira BioSciences by 185.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 246,621 shares of the company’s stock worth $8,321,000 after acquiring an additional 160,149 shares during the period. Finally, Boston Partners increased its stake in Pacira BioSciences by 105.4% during the 3rd quarter. Boston Partners now owns 108,509 shares of the company’s stock worth $3,329,000 after acquiring an additional 55,679 shares during the period. Institutional investors own 99.73% of the company’s stock.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the transaction, the director now owns 22,127 shares in the company, valued at $677,086.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.